Data of the study are protected under the protection of health data regulation set by the French National Commission on Informatics and Liberty (Commission Nationale de l'Informatique et des Libertés, CNIL). The data can be available upon request to Nathalie Pecollo (<n.pecollo@eren.smbh.univ-paris13.fr>), after a consultation with the steering committee of the NutriNet-Santé study. The French law forbids us to provide free access to NutriNet-Santé data; access could be exceptionally granted by the steering committee after legal verification of the use of the data.

Introduction {#sec009}
============

Obesity and overweight nowadays affect a large share of the world's population: in 2016, 13% of adults aged over 18 were estimated to be obese and 39% to be overweight \[[@pmed.1003256.ref001]\]. The prevalence of overweight and obesity has risen continuously during the last century, in particular in low-income countries as well as in low-income groups in high-income countries, in both adults and children \[[@pmed.1003256.ref002]\]. In France, almost half of adults were overweight or obese and 17% were obese in 2015 \[[@pmed.1003256.ref003]\]. Obesity is not only a major risk factor of metabolic diseases (such as coronary heart disease, ischemic stroke, type 2 diabetes \[[@pmed.1003256.ref001]\]) and cancer \[[@pmed.1003256.ref004],[@pmed.1003256.ref005]\], but it is also a metabolic disease itself (Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems \[ICD-10\] code E66). The physiological and psychological consequences of obesity also significantly impair the quality of life and constitute a further burden for health systems \[[@pmed.1003256.ref006]\].

Prevention of chronic diseases has therefore been considered a public health challenge in the past decades \[[@pmed.1003256.ref002]\]. Besides physical activity, the nutritional quality of the diet is a major modifiable risk factor for weight management, with strong levels of evidence for protective factors (i.e., dietary fibre, Mediterranean diets) and risk factors (i.e., high energy density, free sugars, sugar sweetened drinks, and Western-type diets) \[[@pmed.1003256.ref005],[@pmed.1003256.ref007]\]. In addition, drivers of the global obesity epidemic might reside in the change in social behaviours and environmental factors (such as built environment) \[[@pmed.1003256.ref008]--[@pmed.1003256.ref010]\]. Changes in the food system are likely to play a key role in the obesity pandemic \[[@pmed.1003256.ref011]\]: they are notably characterized by increased supply of affordable, hyperpalatable energy-dense food products, along with sophisticated distribution systems to improve accessibility and convenience and intensive food marketing campaigns. These trends in the food systems were accompanied by major dietary changes in the last decades. In particular, industrially processed products and especially ultra-processed food (UPF) consumption drastically rose \[[@pmed.1003256.ref012]\] representing already 50%--60% of total daily energy in some high-income countries \[[@pmed.1003256.ref013]--[@pmed.1003256.ref016]\]. UPFs have a poorer nutritional quality (often high in energy, salt, free sugars, and saturated fats and low in fibre and vitamins \[[@pmed.1003256.ref013]--[@pmed.1003256.ref015],[@pmed.1003256.ref017]--[@pmed.1003256.ref024]\]) compared to unprocessed food. Another characteristic of UPFs is that they are obtained after sequences of several processes, such as high-temperature extrusion, moulding, and pre-frying, and include several food additives and industrial ingredients used to imitate or enhance sensory qualities of foods or to disguise unpalatable aspects of the final product; they are also often in contact with synthetic packaging materials for long periods \[[@pmed.1003256.ref025]\].

Recent evidence suggests adverse associations between UPF consumption and several chronic diseases \[[@pmed.1003256.ref026]\], including studies conducted in the framework of the NutriNet-Santé cohort that have shown positive associations with risks of cancer \[[@pmed.1003256.ref027]\], cardiovascular diseases \[[@pmed.1003256.ref024]\], depressive symptoms \[[@pmed.1003256.ref028]\], type 2 diabetes \[[@pmed.1003256.ref029]\], and all-cause mortality \[[@pmed.1003256.ref030]\]. Regarding weight change and obesity (a risk factor for the latter chronic diseases \[[@pmed.1003256.ref005],[@pmed.1003256.ref031]--[@pmed.1003256.ref033]\]), a 2-week randomized cross-over trial \[[@pmed.1003256.ref034]\] showed that an ultra-processed diet versus an unprocessed one led to an increased daily energy intake of around 500 kcal which was highly correlated with weight gain. Consistently, several cross-sectional and ecological studies have substantiated a positive association between UPF consumption and obesity \[[@pmed.1003256.ref023],[@pmed.1003256.ref035]--[@pmed.1003256.ref039]\], but prospective studies are lacking, as only 2 of them---one in Spain \[[@pmed.1003256.ref040]\] and one in Brazil \[[@pmed.1003256.ref041]\]---were conducted; both relied on dietary data from food frequency questionnaires (FFQs) and studied the contribution of UPF to energy intake and therefore did not account for low-calorie and artificially sweetened products.

This large-scale prospective study aimed to investigate the associations between UPF consumption and body mass index (BMI) change, as well as the risk of overweight and obesity, among adults from the large-scale NutriNet-Santé cohort.

Methods {#sec010}
=======

Population {#sec011}
----------

The NutriNet-Santé study is a French web-based ongoing cohort study, launched in 2009 to investigate the associations between diet and health. The NutriNet-Santé cohort has been previously described in detail \[[@pmed.1003256.ref042]\]. Briefly, participants from all regions of France with access to the internet have been continuously recruited, on a voluntary basis, from the general population since May 2009. Vast multimedia campaigns (television, radio, national and regional newspapers, posters, internet) called for volunteers by providing details on the study\'s specific website where volunteers can subscribe. A relay of information was also maintained on a large number of websites (national institutions, city councils, private firms, web organisations). A billboard advertising campaign was also available through professional channels (doctors, pharmacists, dentists, business partners, municipalities, etc.) \[[@pmed.1003256.ref043]\]. The online NutriNet-Santé platform is designed to send an average of 1 questionnaire per month, allowing us to collect additional information on various research topics beyond diet (e.g., sleep duration, environmental exposures, mental health, cooking practices). The NutriNet-Santé study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of the French Institute for Health and Medical Research (IRB Inserm No. 0000388FWA00005831) and by the National Commission on Informatics and Liberty (CNIL No. 908450 and No. 909216). The study is registered at clinicaltrials.gov as NCT03335644. Some other information can be accessed on the website <https://info.etude-nutrinet-sante.fr/en>. Electronic informed consent was obtained from each participant. All methods have been described in line with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement (see [S1 STROBE Checklist](#pmed.1003256.s001){ref-type="supplementary-material"}).

Data collection {#sec012}
---------------

### Dietary data {#sec013}

Dietary data were collected at baseline using a kit of 3 non-consecutive web-based 24-hour records, randomly assigned over a 2-week period (2 during weekdays and 1 during the weekend). Participants were invited to declare every beverage and food consumed that day, during the 3 main meals and any additional eating occasions. Portion sizes were assessed using validated photographs or usual containers. In this prospective analysis, we averaged the mean dietary intakes from the baseline 24-hour dietary records and considered these as baseline usual dietary intakes. Nutrient intakes were calculated using a food composition table, listing more than 3,500 food items \[[@pmed.1003256.ref044]\]. The contribution of macronutrients to total energy intake was calculated. Dietary underreporting was identified with the method proposed by Black, using the basal metabolic rate and Goldberg cut-off, in order to screen participants with abnormally low energy intakes, and energy underreporters (20.0% of the cohort) were excluded \[[@pmed.1003256.ref045]\]. Detailed methodology for underreporting is presented in Method A in [S1 Appendix](#pmed.1003256.s002){ref-type="supplementary-material"}. Validation studies comparing these web-based dietary questionnaires to interviews by dieticians \[[@pmed.1003256.ref046]\] or urinary and plasma biomarkers \[[@pmed.1003256.ref047],[@pmed.1003256.ref048]\] of nutritional status demonstrated a good validity of the collected data.

### Food processing classification {#sec014}

Foods and beverages of the NutriNet-Santé composition table were categorized according to the extent of processing, into one of the 4 NOVA categories (unprocessed/minimally processed foods, processed culinary ingredients, processed foods, UPFs) \[[@pmed.1003256.ref025],[@pmed.1003256.ref049]\]. This categorization was performed by a team of 3 dietitians and 5 researchers \[[@pmed.1003256.ref039]\]. Home-made and artisanal foods were identified and decomposed using standardized recipes, and the classification was applied to their ingredients. In case of uncertainty, classification was based on the consensus reached in the team. Details and examples are provided in Method B in [S1 Appendix](#pmed.1003256.s002){ref-type="supplementary-material"}.

### Anthropometric data {#sec015}

Self-reported weight and height were collected using a web-based questionnaire at baseline, and every 6 months thereafter between May 2009 and June 2019, and were used to compute repeated data of BMI (BMI = (weight \[kilograms\] ÷ height^2^ \[meters\]). Obesity was identified using international standards as a BMI ≥ 30 kg/m^2^ and overweight including obesity was identified as a BMI ≥ 25 kg/m^2^ \[[@pmed.1003256.ref002]\]. This web-based questionnaire was validated by comparison with standardized clinical measurements \[[@pmed.1003256.ref050]\].

### Covariates {#sec016}

Sociodemographic data were collected at baseline using a self-administered questionnaire \[[@pmed.1003256.ref051]\]. Sex, age, educational level (no higher education, \<2 years after high school, ≥2 years after high school), marital status (living alone or not), and smoking status (current, former, or never smoker) were collected for each participant. Physical activity was computed using the validated International Physical Activity Questionnaire, completed at baseline (low, moderate, and high physical activity levels) \[[@pmed.1003256.ref052]\] (details in Method C in [S1 Appendix](#pmed.1003256.s002){ref-type="supplementary-material"}). Data about time spent for screen watching and sedentary behaviours were also available. Several indicators of the nutritional quality of the diet were also computed based on average dietary intakes from baseline 24-hour dietary records and were used as covariates: daily nutrient intake (sugar, fibre, sodium, and saturated fatty acid \[SFA\]) calculated using the food composition database; consumptions of several food groups (fruit, vegetables, and sugary drinks); and healthy and Western dietary patterns, derived from Principal Component Analysis (see Method D in [S1 Appendix](#pmed.1003256.s002){ref-type="supplementary-material"}).

Statistical analysis {#sec017}
--------------------

Analyses for this specific article were hypothesis oriented in order to investigate the relationship between UPF consumption and weight gain or prospective occurrence of overweight or obesity. No specific analysis plan has been pre-published for the present article, but all analyses were pre-planned by the authors at the time of conception and design of the present study, except one non-prespecified analysis that was performed to comply with peer-review requirements (mixed models with continuous exposure).

Adults (aged between 18.0 and 73.3 years old) who completed at least two 24-hour records and who were followed up for at least 6 months, with no missing anthropometric data at baseline and with at least 2 available anthropometric questionnaires, were included. Details are shown in the flowchart ([Fig 1](#pmed.1003256.g001){ref-type="fig"}).

![Flowchart for study population, NutriNet-Santé cohort, 2009--2019.](pmed.1003256.g001){#pmed.1003256.g001}

For each participant, the proportion (in weight, percentage of grams per day) of UPF in the total diet was calculated. The proportion of UPF in the diet was determined with a weight ratio rather than an energy ratio in order to better take into account food items that do not provide any energy (e.g., artificially sweetened beverages) and non-nutritional issues related to food processing (e.g., food additives, neo-formed contaminants and alterations to the structure of raw foods).

The population's characteristics were described according to sex-specific quartiles of the proportion of UPF in the diet (quartiles were built separately in men and women according to the specific distribution and cut-offs in each group; matching quartiles were then combined). For all covariates except physical activity, ≤5% of values were missing and imputed to the modal (categorical variables) or median (continuous variables) values. A missing class was created for physical activity (14% missing). Multiple Imputation by Chained Equations (MICE) method was also tested \[[@pmed.1003256.ref053]\].

We measured the associations between the proportion of UPF in the diet (for an absolute increment of 10 in the percentage of UPF in the diet coded as a continuous variable, and as sex-specific quartiles) and BMI change over time using mixed models for repeated measures (PROC MIXED in SAS), with UPF as fixed effect and intercept and time as random effects, with unstructured covariance structure. Time was defined as the chronological number of the anthropometric questionnaire (approximately 1 year of follow-up = 2 time units), from which the corresponding data were collected. The outcome modelled was the absolute change in BMI (Δ BMI). Models were adjusted for age, sex, educational level, smoking status, marital status, physical activity level, energy intake, alcohol intake, and number of dietary records. Additional adjustments were tested in different models: for sugar (grams per day), fibre (grams per day), sodium (grams per day), and SFA intake (grams per day) (to adjust for the nutritional quality of UPF); for dietary patterns (to capture the overall quality of the diet); and for consumptions of fruit, vegetables (grams per day), and sugary drinks (millilitres per day) (convincingly linked to the risk of weight gain according to the World Cancer Research Fund/American Institute for Cancer Research \[WCRF/AICR\]) \[[@pmed.1003256.ref005]\].

Associations between quartiles of UPF consumption and overweight and obesity risk were assessed using Cox proportional hazard models with age as timescale. Schoenfeld residuals were generated to confirm the risk proportionality assumptions. Martingale residuals were generated to confirm the assumption of linearity for the percentage UPF in the diet when used as continuous. Participants contributed person-time to the Cox model until the date of onset of overweight or obesity for cases (defined as the mid-point date between the anthropometrics questionnaire in which the participant's self-reported weight corresponding to overweight or obesity, and the previous one \[[@pmed.1003256.ref054]\]) and the date of last completed anthropometrics questionnaire for non-cases. Similar adjustments as those used in BMI change analyses were used. Analyses were tested with and without adjustment for baseline BMI.

### Sensitivity and secondary analyses {#sec018}

Associations were also tested in stratified analyses for sex, age, intake of sugar and SFA, and smoking status, as well as in sensitivity analyses excluding cases occurring within the first 2 years.

In secondary analyses, we explored the associations between the proportion of unprocessed/minimally processed foods in the diet (first category of NOVA) in association with the risks of overweight and obesity. We also investigated the associations between the consumption amount (in grams per day) of UPF and risks of overweight and obesity, as well as the amounts of the different UPF groups (beverages, dairy products, fats and sauces, fruits and vegetables, meat, fish and egg, starchy foods and breakfast cereals, sugary products, and salty snacks).

Statistical analyses were performed using SAS 9.4 and R Studio. All tests were two-sided, and *P* \< 0.05 was considered significant.

Results {#sec019}
=======

Descriptive results {#sec020}
-------------------

Baseline characteristics of the study population (*n* = 110,260, among which women made up 78.2% women; mean age \[SD\] = 43.1 \[14.6\]) are described in [Table 1](#pmed.1003256.t001){ref-type="table"}. The density plot of the proportion of UPF in the diet in the study sample is presented in Fig A in [S1 Appendix](#pmed.1003256.s002){ref-type="supplementary-material"}. Compared to participants with a lower proportion of UPF in their diet (first quartile), participants in the fourth quartile tended to be younger, were more likely to be smokers, were less likely to be single, were higher educated (≥ 2years after high school), and had a lower physical activity level. They had also higher sodium, sugar, SFA, and energy intake and lower intakes of dietary fibre and alcohol.

10.1371/journal.pmed.1003256.t001

###### Baseline characteristics of the study population according to sex-specific quartiles of UPF consumption (*N* = 110,260), NutriNet-Santé cohort, France, 2009--2019[^a^](#t001fn001){ref-type="table-fn"}.

![](pmed.1003256.t001){#pmed.1003256.t001g}

                                                                                        All participants   Quartile[^b^](#t001fn002){ref-type="table-fn"} 1   Quartile[^b^](#t001fn002){ref-type="table-fn"} 2   Quartile[^b^](#t001fn002){ref-type="table-fn"} 3   Quartile[^b^](#t001fn002){ref-type="table-fn"} 4
  ------------------------------------------------------------------------------------- ------------------ -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  **UPF (%)**                                                                           17.1 (10.3)        7.5 (2.1)                                          13.2 (1.8)                                         18.7 (2.2)                                         32.4 (9.6)
  **Age, years**                                                                        43.1 (14.6)        47.7 (13.7)                                        44.9 (14.3)                                        42.4 (14.6)                                        37.5 (14.1)
  **Sex, women, *n* (%)**                                                               86,253 (78.2)      21,601 (78.2)                                      21,574 (78.2)                                      21,553 (78.2)                                      21,525 (78.2)
  **Educational level, *n* (%)**                                                                                                                                                                                                                                    
  \<High school degree                                                                  20,013 (18.1)      5,212 (18.9)                                       4,941 (17.9)                                       4,873 (17.7)                                       4,987 (18.1)
  \<2 years after high school                                                           19,061 (17.3)      4,145 (15.0)                                       4,300 (15.6)                                       4,764 (17.3)                                       5,852 (21.3)
  ≥2 years after high school                                                            71,186 (64.6)      18,252 (66.1)                                      18,335 (66.5)                                      17,919 (65.0)                                      16,680 (60.6)
  **Marital status, *n* (%)**                                                                                                                                                                                                                                       
  Single (living alone)                                                                 32,532 (29.5)      7,380 (26.7)                                       7,383 (26.8)                                       7,990 (29.0)                                       9,779 (35.5)
  In couple                                                                             77,728 (70.5)      20,229 (73.3)                                      20,193 (73.2)                                      19,566 (71.0)                                      17,740 (64.5)
  **BMI, kg/m^2^**                                                                      23.8 (4.6)         23.8 ± 4.4                                         23.8 ± 4.3                                         23.8 ± 4.5                                         23.9 ± 5.0
  **Smoking status, *n* (%)**                                                                                                                                                                                                                                       
  Current                                                                               18,731 (17.0)      4,181 (15.1)                                       4,319 (15.7)                                       4,526 (16.4)                                       5,705 (20.7)
  Former                                                                                36,243 (32.9)      10,564 (38.3)                                      9,373 (34.0)                                       8,852 (32.1)                                       7,454 (27.1)
  Never                                                                                 55,286 (50.1)      12,864 (46.6)                                      13,884 (50.3)                                      14,178 (51.4)                                      14,360 (52.2)
  **IPAQ physical activity level, *n* (%)**[^**c**^](#t001fn003){ref-type="table-fn"}                                                                                                                                                                               
  High                                                                                  31,638 (33.2)      9,152 (38.0)                                       8,222 (34.0)                                       7,671 (32.2)                                       6,593 (28.3)
  Moderate                                                                              40,825 (42.8)      10,171 (42.2)                                      10,516 (43.6)                                      10,251 (43.0)                                      9,887 (42.4)
  Low                                                                                   22,881 (24.0)      4,748 (19.7)                                       5,391 (22.3)                                       5,918 (24.8)                                       6,824 (29.3)
  **Energy intake, kcal/d**                                                             1,893.2 (503.9)    1,816.2 (473.8)                                    1,896.5 (489.0)                                    1,925.5 (507.8)                                    1,934.70 (534.5)
  **Alcohol intake, g/d**                                                               7.9 (12.7)         8.8 (13.5)                                         8.7 (13.0)                                         7.8 (12.4)                                         6.2 (11.7)
  **Sodium intake, mg/d**                                                               2,683.9 (954.6)    2,536.2 (919.5)                                    2,696.7 (931.5)                                    2,762.0 (962.1)                                    2,741.0 (987.4)
  **SFA, g/d**                                                                          32.8 (13.2)        29.7 (12.2)                                        32.7 (12.7)                                        33.9 (13.2)                                        34.74 (13.9)
  **Dietary fibre, g/d**                                                                19.6 (7.6)         21.0 (8.1)                                         20.0 (7.4)                                         19.7 (7.3)                                         17.7 (7.4)
  **Sugar, g/d**                                                                        92.2 (35.4)        85.3 (33.9)                                        90.9 (32.7)                                        93.7 (34.0)                                        99.1 (39.1)

^a^Values are means (SDs) or *n* (%).

^b^Sex-specific quartiles of the proportion of UPF intake in the total quantity of food consumed. Cut-offs for quartiles were 10.2, 15.5, and 22.5 for men and 9.9, 15.2, and 22.1 for women, respectively.

^c^Available for 95,344 participants. Participants were categorized into the "high," "moderate," and "low" categories according to IPAQ guidelines \[[@pmed.1003256.ref052]\] (Method C in [S1 Appendix](#pmed.1003256.s002){ref-type="supplementary-material"}).

**Abbreviations:** BMI, body mass index; IPAQ, International Physical Activity Questionnaire; SFA, saturated fatty acid; UPF, ultra-processed food

UPF and BMI change {#sec021}
------------------

BMI change over time by sex-specific quartiles of UPF proportion in the diet is shown in [Fig 2](#pmed.1003256.g002){ref-type="fig"}, and results of mixed models are presented in [Table 2](#pmed.1003256.t002){ref-type="table"}. Participants in the fourth quartile of UPF consumption had higher BMI at baseline (β coefficients for Q4 \> 0) compared to those in the first quartile (reference in the model). While an increase of BMI was observed in all UPF quartiles (β coefficients for time significantly \> 0), the BMI gain appeared to be higher for participants in quartiles 2, 3, and 4 compared to individuals from quartile 1 (β coefficients for interactions terms between time and quartile \> 0); the magnitude of BMI increase was the highest for Q4 (βQ4 × time = 0.04 \[0.04--0.05\], *P* \< 0.001, model 1). In continuous models, we observed a positive association between an absolute increment of 10 in the percentage of UPF in the diet and gain in BMI (β time × UPF~continuous~ = 0.02 (0.01--0.02), *P* \< 0.001, model 1).The findings remained similar after further adjustments for intake of sugar, sodium, SFA, and dietary fibre (model 2), for healthy and Western dietary patterns (model 3), and for intake of fruit and vegetables and sugary drinks (model 4).

![BMI change over time in the four quartiles of the proportion of UPF in the diet, NutriNet-Santé, 2009--2019 (*n* = 110,260).\
The average BMI for each year and each quartile of UPF intake is presented along with the 95% CI of the mean. BMI, body mass index; UPF, ultra-processed food](pmed.1003256.g002){#pmed.1003256.g002}

10.1371/journal.pmed.1003256.t002

###### Associations between sex-specific quartiles of UPF consumption and BMI change, NutriNet-Santé cohort, France, 2009--2019 (*N* = 110,260).

![](pmed.1003256.t002){#pmed.1003256.t002g}

  Proportion of UPF in the diet                                                                            Model 1                Model 2   Model 3                Model 4                                                            
  -------------------------------------------------------------------------------------------------------- ---------------------- --------- ---------------------- --------- ----------------------- --------- ---------------------- ---------
  **Continuous**                                                                                                                                                                                                                      
  UPF~continuous~[^b^](#t002fn003){ref-type="table-fn"}                                                    0.25 (0.22 to 0.27)    \<0.001   0.20 (0.17 to 0.21)    \<0.001   0.14 (0.12 to 0.17)     \<0.001   0.21 (0.19 to 0.24)    \<0.001
  Time (average BMI gain/time unit)[^c^](#t002fn004){ref-type="table-fn"}                                  0.02 (0.01 to 0.02)    \<0.001   0.02 (0.01 to 0.02)    \<0.001   0.02 (0.01 to 0.02)     \<0.001   0.02 (0.01 to 0.02)    \<0.001
  Time × UPF~continuous~[^d^](#t002fn005){ref-type="table-fn"}                                             0.02 (0.01 to 0.02)    \<0.001   0.02 (0.01 to 0.02)    \<0.001   0.02 (0.01 to 0.02)     \<0.001   0.02 (0.01 to 0.02)    \<0.001
  **Sex-specific quartiles**                                                                                                                                                                                                          
  Quartile 2 (BMI difference at baseline with the reference--Q1)                                           0.11 (0.04 to 0.19)    0.003     0.02 (-0.05 to 0.09)   0.6       −0.00 (−0.07 to 0.07)   0.9       0.04 (−0.03 to 0.12)   0.2
  Quartile 3 (BMI difference at baseline with the reference--Q1)                                           0.24 (0.16 to 0.31)    \<0.001   0.11 (0.03 to 0.18)    0.004     0.05 (−0.02 to 0.13)    0.1       0.13 (0.06 to 0.21)    \<0.001
  Quartile 4 (BMI difference at baseline with the reference--Q1)                                           0.60 (0.52 to 0.67)    \<0.001   0.42 (0.34 to 0.51)    \<0.001   0.30 (0.23 to 0.38)     \<0.001   0.43 (0.35 to 0.52)    \<0.001
  Time (BMI gain/time unit in the reference--Q1)                                                           0.03 (0.03 to 0.04)    \<0.001   0.03 (0.03 to 0.04)    \<0.001   0.03 (0.03 to 0.04)     \<0.001   0.03 (0.03 to 0.04)    \<0.001
  Time × quartile 2 (additional BMI gain/time unit[^e^](#t002fn006){ref-type="table-fn"} compared to Q1)   0.01 (0.003 to 0.01)   0.001     0.01 (0.004 to 0.02)   0.001     0.01 (0.003 to 0.02)    0.001     0.01 (0.003 to 0.02)   0.002
  Time × quartile 3 (additional BMI gain/time unit[^e^](#t002fn006){ref-type="table-fn"} compared to Q1)   0.02 (0.01 to 0.02)    \<0.001   0.01 (0.01 to 0.02)    \<0.001   0.02 (0.01 to 0.02)     \<0.001   0.02 (0.01 to 0.02)    \<0.001
  Time × quartile 4 (additional BMI gain/time unit[^e^](#t002fn006){ref-type="table-fn"} compared to Q1)   0.04 (0.04 to 0.05)    \<0.001   0.04 (0.04 to 0.05)    \<0.001   0.04 (0.04 to 0.05)     \<0.001   0.04 (0.04 to 0.05)    \<0.001

Model 1 = mixed model for repeated measure, with intercept and time as random, adjusted for age, sex, marital status (living alone or not), educational level (\<high school, \<2 years after school, ≥2 years after high school), physical activity level (high, moderate, low), smoking status (never, former, current), alcohol consumption (continuous), energy intake (continuous), and number of dietary records (continuous); model 2 = model 1 + intakes of sugar, sodium, SFAs, and dietary fibre (continuous); model 3 = model 1 + healthy and Western dietary patterns (continuous); model 4 = model 1 + consumption of fruit and vegetables and sugary drinks (continuous). Time unit: average time difference between two anthropometric questionnaires (approximately 6 months). Sex-specific quartiles of the proportion of UPF intake in the total quantity of food consumed. Cut-offs for quartiles were 10.2, 15.5, and 22.5 for men and 9.9, 15.2, and 22.1 for women.

^a^Estimates β of parameters are interpreted as absolute variation of BMI (Δ BMI).

^b^Interpreted as BMI difference at baseline associated with an absolute increment of 10 in the percentage of UPF in the diet.

^c^Interpreted as BMI gain/time unit when the proportion of UPF in the diet = 0.

^d^Interpreted as BMI gain/time unit associated with an absolute increment of 10 in the percentage of UPF in the diet.

^e^Additional BMI gain/time unit = BMI gain/time unit in quartile 2, quartile 3, or quartile 4, in addition to BMI gain/time unit in Q1.

**Abbreviations:** BMI, body mass index; Q1, quartile 1; SFA, saturated fatty acid; UPF, ultra-processed food

UPF and risk of overweight {#sec022}
--------------------------

Analyses related to overweight (including obesity) risk were performed on a sample of 55,037 non-overweight participants at baseline ([Table 3](#pmed.1003256.t003){ref-type="table"}). During follow-up (260,304 person-years, median follow-up time = 4.1 years), 7,063 participants became overweight. The proportional hazard assumptions of the Cox models were met, as well as the linearity assumption for the continuous model (Fig B in [S1 Appendix](#pmed.1003256.s002){ref-type="supplementary-material"}). Participants with a higher proportion of UPF in their diet had a higher risk of becoming overweight (hazard ratio \[HR\] for an absolute increment of 10 in the percentage of UPF in the diet = 1.11 \[1.08--1.14\], *P* \< 0.001). These trends were significant from the second quartile of UPF intake and were the strongest in the fourth quartile: HR~Q4vs.Q1~ = 1.26 (1.18 to 1.35), *P*~trend~ \< 0.001. These associations remained significant after adjustment for several indicators of the nutritional quality of the diet.

10.1371/journal.pmed.1003256.t003

###### Associations between UPF intake and risks of overweight and obesity from Cox proportional hazard models, NutriNet-Santé cohort, 2009--2019.

![](pmed.1003256.t003){#pmed.1003256.t003g}

                            Proportion of UPF in the diet[^a^](#t003fn002){ref-type="table-fn"}                                                                                                                                               
  ------------------------- --------------------------------------------------------------------- ------------------- ------------------- ------------------- -------------------- ---------------------------------------------------------- ---------
  **Overweight**            **Q1**                                                                **Q2**              **Q3**              **Q4**                                   **Continuous**[^**b**^](#t003fn003){ref-type="table-fn"}   
                            **HR**                                                                **HR (95% CI)**     **HR (95% CI)**     **HR (95% CI)**     ***P***~**trend**~   **HR (95% CI)**                                            ***P***
  ***N* cases/non-cases**   1,666/12,092                                                          1,706/12,054        1,830/11,930        1,861/11,898                             7,063/47,974                                               
  Model 1                   1                                                                     1.06 (1.00--1.14)   1.19 (1.11--1.28)   1.26 (1.18--1.35)   \<0.001              1.11 (1.08--1.14)                                          \<0.001
  Model 2                   1                                                                     1.07 (1.00--1.14)   1.19 (1.12--1.28)   1.30 (1.21--1.39)   \<0.001              1.11 (1.08--1.14)                                          \<0.001
  Model 3                   1                                                                     1.06 (0.99--1.13)   1.18 (1.10--1.26)   1.24 (1.16--1.33)   \<0.001              1.10 (1.08--1.13)                                          \<0.001
  Model 4                   1                                                                     1.05 (0.98--1.13)   1.17 (1.09--1.25)   1.22 (1.14--1.31)   \<0.001              1.10 (1.07--1.13)                                          \<0.001
  Model 5                   1                                                                     1.05 (0.98--1.13)   1.17 (1.09--1.25)   1.22 (1.13--1.31)   \<0.001              1.10 (1.07--1.13)                                          \<0.001
  **Obesity**               **Q1**                                                                **Q2**              **Q3**              **Q4**                                   **Continuous**                                             
                            **HR**                                                                **HR (95% CI)**     **HR (95% CI)**     **HR (95% CI)**     ***P***~**trend**~   **HR (95% CI)**                                            ***P***
  ***N* cases/non-cases**   687/17,280                                                            723/17,245          803/17,166          853/17,114                               3,066/68,805                                               
  Model 1                   1                                                                     1.05 (0.94--1.16)   1.10 (1.00--1.22)   1.15 (1.04--1.28)   0.005                1.09 (1.05--1.13)                                          \<0.001
  Model 2                   1                                                                     1.09 (0.98--1.21)   1.26 (1.13--1.39)   1.41 (1.27--1.57)   \<0.001              1.19 (1.15--1.23)                                          \<0.001
  Model 3                   1                                                                     1.05 (0.95--1.17)   1.11 (1.00--1.23)   1.16 (1.05--1.30)   0.003                1.10 (1.06--1.14)                                          \<0.001
  Model 4                   1                                                                     1.06 (0.95--1.18)   1.12 (1.01--1.24)   1.20 (1.08--1.33)   \<0.001              1.11 (1.07--1.15)                                          \<0.001
  Model 5                   1                                                                     1.05 (0.95--1.17)   1.11 (1.00--1.23)   1.15 (1.03--1.28)   0.009                1.10 (1.05--1.14)                                          \<0.001

Qi \[i = 1--4\] = Quartile, *n* = 55,307 for overweight analyses and 71,871 for obesity analyses. Model 1 was a multi-adjusted Cox proportional hazard model adjusted for age (timescale), sex, educational level (\<high school, \<2 years after school, ≥2 years after high school), marital status (living alone or not), baseline BMI (continuous), physical activity (high, moderate, low), smoking status (never, former, current), alcohol intake (continuous), number of 24-hour dietary records (continuous), and energy intake (continuous); model 2 = model 1 unadjusted for baseline BMI; model 3 = model 1 + intakes of sodium, sugar, SFAs, and dietary fibre (continuous); model 4 = model 1 + healthy and Western dietary patterns (continuous); model 5 = model 1 + consumption of fruit and vegetables, and sugary drinks (continuous).

^a^Cut-offs for quartiles were 9.9, 14.9, and 21.5 for men and 9.6, 14.5, and 21.1 for women in the overweight analyses; and 9.8, 14.8, and 21.2 for men and 9.6, 14.5, and 21.1 for women in the obesity analyses.

^b^HR for an absolute increment of 10 in the percentage of UPF in the diet.

**Abbreviations:** BMI, body mass index; HR, hazard ratio; SFA, saturated fatty acid; UPF, ultra-processed food

UPF and risk of obesity {#sec023}
-----------------------

Analyses related to obesity risk were performed on a sample of 71,871 participants non-obese at baseline ([Table 3](#pmed.1003256.t003){ref-type="table"}). During follow-up (365,344 person-years, median follow-up time = 5.0 years), 3,066 participants became obese. The proportional hazard assumptions of the Cox models were met, as well as the linearity assumption for the continuous model (Fig B in [S1 Appendix](#pmed.1003256.s002){ref-type="supplementary-material"}). Participants with a higher proportion of UPF in their diet had a higher risk of obesity (HR for an absolute increment of 10 in the percentage of UPF in the diet = 1.09 \[1.05--1.13\], *P* \< 0.001). These trends were statistically significant starting the third quartile, were the strongest in the fourth quartile (HR~Q4vs.Q1~ = 1.15 \[1.04--1.28\], *P*~trend~ = 0.005), and remained stable across all models with further adjustments.

Sensitivity and secondary analyses {#sec024}
----------------------------------

Using the proportion of UPF weighted by energy (rather than quantity) or the absolute consumption amount (in grams) of UPF did not change the findings (Table A in [S1 Appendix](#pmed.1003256.s002){ref-type="supplementary-material"}). Ultra-processed beverages, dairy products, fats and sauces, and meat, fish, and egg were each associated with increased overweight and obesity risks, while ultra-processed starchy foods and breakfast cereals were associated with an increased risk of overweight but not obesity (Table B in [S1 Appendix](#pmed.1003256.s002){ref-type="supplementary-material"}). In contrast, there was no evidence for a positive association between these food groups' consumption in their non--ultra-processed form and increased overweight and obesity risks (*P* \> 0.05), except for products based on meat, fish, or eggs (e.g., unprocessed red and white meat, smoked meats, ham with no added nitrates or additives). In the case of these latter products, the HR for a 100-g increase was 1.16 (1.12--1.20; *P* \< 0.0001) for overweight, and HR = 1.17 (1.11--1.22; *P* \< 0.001) for obesity.

In secondary analyses, the consumption of unprocessed or minimally processed foods was inversely associated with overweight risk (HR for an absolute increment of 10 in the percentage of unprocessed/minimally processed foods in the diet = 0.95 \[0.92--0.97\], *P* \< 0.001), but statistical significance was not reached in obesity analyses (HR = 0.97 \[0.94--1.00\], *P* = 0.1).

The associations with overweight and obesity risk were statistically significant in all strata of the population investigated (age groups, subgroups according to sugar and SFA intake, smoking status) except in men, probably due to weaker statistical power (Table A in [S1 Appendix](#pmed.1003256.s002){ref-type="supplementary-material"}). The findings remained robust throughout all sensitivity models (e.g., exclusion of cases occurring during the first 2 years and further adjustments).

Discussion {#sec025}
==========

In this large prospective cohort, participants consuming more UPFs tended to present higher BMI increase during follow-up and had increased risk of becoming overweight and obese, independently of their baseline BMI. These associations remained statistically significant after adjusting for a wide range of socioeconomic and lifestyle factors, and after further adjustments for several indicators of the nutritional quality of the diet.

The increased weight gain in participants consuming more UPFs observed in our study is consistent with several epidemiological studies. A recent study showed that higher consumers of UPFs had a higher risk of weight gain \[[@pmed.1003256.ref041]\]. Moreover, in a recent randomized controlled trial \[[@pmed.1003256.ref034]\], Hall and colleagues allocated participants either to an ultra-processed or minimally processed diet for 2 weeks immediately followed by the alternate diet for 2 weeks. The ultra-processed diet led to an increased energy intake (+508 ± 106 kcal/d), which was highly correlated with weight gain (0.8 ± 0.3 kg \[*P* = 0.01\]), versus a weight loss of 1.1 ± 0.3 kg during the unprocessed diet.

We also observed an increased risk of overweight and obesity in participants consuming more UPFs. Several national cross-sectional studies have shown positive associations between UPF consumption and BMI \[[@pmed.1003256.ref036],[@pmed.1003256.ref038]\]. Furthermore, these results are is in line with 2 ecological studies suggesting that increased purchases and household availability of UPF were associated with higher BMI and higher obesity prevalence \[[@pmed.1003256.ref037],[@pmed.1003256.ref055]\]. Prospective studies undertaken in Spain \[[@pmed.1003256.ref040]\] and Brazil \[[@pmed.1003256.ref041]\] showed increased risk of overweight/obesity linked to higher UPF intake of a magnitude similar to what we found in our study (HR~Q4vs.Q1~ = 1.26 \[1.10--1.45\] for the Spanish study and HR~Q4vs.Q1~ = 1.20 \[1.03--1.40\] for the Brazilian study). The latter study found no association with obesity risk, but it only included overweight participants at baseline and had a shorter follow-up period (3.8 years versus 5.0 years for our study) and participants were older (51.3 years old versus 43.1 for our study). These studies used the contribution of UPFs to daily energy intake, whereas we used the contribution of UPFs to daily quantity of food intake; comparison with our findings is therefore not straightforward.

The positive association observed between UPFs and weight gain may be partly explained by their poorer nutritional quality. Indeed, on average, UPFs tend to be higher in saturated fats, sugar, and energy and poorer in dietary fibre \[[@pmed.1003256.ref013]--[@pmed.1003256.ref015],[@pmed.1003256.ref017]--[@pmed.1003256.ref024]\], i.e., nutritional factors known to favour obesity onset \[[@pmed.1003256.ref005]\]. However, it is important to note that all analyses were adjusted for daily energy intake, and results remained statistically significant after adjustment for multiple nutritional parameters (key nutrients and food groups, dietary patterns). Therefore, the poor nutritional quality of these foods does not appear to be entirely responsible for the observed association with weight gain, suggesting that non-nutritional bioactive compounds or factors within UPFs may also contribute to explain the findings. First, food processing may affect the food structure and, for two foods with the same nutritional composition, lead to different health impacts \[[@pmed.1003256.ref056]\]. Indeed, the food matrix can influence nutrient and other bioactive food component delivery and bioavailability as well as gut microbiota profile and integrity \[[@pmed.1003256.ref056]\], potentially leading to weight gain in case deleterious nutrients are delivered faster from the food matrix. Second, some food additives, which are specific of UPFs, might be involved in obesity aetiology. For example, saccharin, an artificial sweetener, could potentiate glucose-stimulated insulin release from isolated pancreatic β-cells \[[@pmed.1003256.ref057]\], leading to insulin resistance and potentially weight gain. Some emulsifiers (carboxymethyl cellulose and polysorbate-80, used in \>1,500 UPFs in France) induced metabolic perturbations, alterations to the gut microbiota, and low-grade inflammation in mice \[[@pmed.1003256.ref058]\]. Carrageenan, a thickening and stabilizing agent, used in \>5,500 products in France and in the top-20 used additives, might increase insulin resistance and inhibit insulin signalling in mouse liver and human HepG2 cells \[[@pmed.1003256.ref059],[@pmed.1003256.ref060]\], which might, in turn, induce weight gain \[[@pmed.1003256.ref061]\]. However, as for most additives, human data on long-term health impacts are still lacking, and potential cocktail effects remain largely unknown. The Europe-funded Additives program will allow us to advance knowledge in this field in the near future \[[@pmed.1003256.ref062]\]. Third, trans fatty acids found in UPFs containing hydrogenated oils have been associated with cardiovascular disease \[[@pmed.1003256.ref063]\] and obesity \[[@pmed.1003256.ref064]\] probably by altering nutrient handling in liver, adipose tissue, and skeletal muscle \[[@pmed.1003256.ref065]\]. Fourth, the long shelf-life of most UPFs increases the risk of contamination from plastic packaging by substances such as bisphenols (which have endocrine-disrupting properties \[[@pmed.1003256.ref066]\]) or phthalates (which are associated with dysregulated sex hormones, obesity, and insulin resistance \[[@pmed.1003256.ref067]\]). A recent study conducted in the US showed that UPF consumption was associated with increased exposure to phthalates \[[@pmed.1003256.ref068]\], which have suggested associations with obesity, especially in children \[[@pmed.1003256.ref069]\]. Lastly, acrylamide, a neo-formed compound created during thermal processing of food as a result of the Maillard reaction, was found to induce adipocyte differentiation and obesity in mice \[[@pmed.1003256.ref070]\]. Furthermore, the increased availability, accessibility, and affordability of these UPFs on the market, in addition to their excessive marketing, might play at least a partial role in these associations, as they contribute to an obesogenic environment \[[@pmed.1003256.ref008],[@pmed.1003256.ref071],[@pmed.1003256.ref072]\], even though we adjusted for energy intake. Therefore, it is important to act on slowing down the obesity epidemic not only through dietary guidelines but also by ensuring the availability of healthy products and the establishment of an environment that encourages healthy behaviours.

While obesity is a health outcome itself (studied as such in the present analysis), it is also a major risk factor of metabolic diseases such as coronary heart disease, ischemic stroke, and type 2 diabetes \[[@pmed.1003256.ref001]\] but also many cancers \[[@pmed.1003256.ref004],[@pmed.1003256.ref005]\]. Studying the associations between UPF consumption and obesity is relevant as it is, given the metabolic and economic burdens of obesity; but it is also relevant given the role of obesity as a risk factor for these other chronic diseases. In one of our previous prospective studies, we found that UPF consumption was associated with an increased risk of type 2 diabetes \[[@pmed.1003256.ref029]\] and that this association was not fully explained by weight gain. We also found associations between UPF consumption and overall cancer risk, and CVD risk in non-obese participants \[[@pmed.1003256.ref024],[@pmed.1003256.ref027]\]. UPF could therefore play both a direct role in the development of CVD, cancer, and T2D, as discussed elsewhere, but also an indirect role through weight gain and obesity as we observe in the present study. This double pathway is already known and well described for other dietary factors, such as fruit and vegetables, a protector against head and neck cancers with a probable level of evidence according to the WCRF \[[@pmed.1003256.ref005]\] through both a direct effect (i.e., DNA methylation, redox status) and an indirect effect through decreasing overweight and obesity risks \[[@pmed.1003256.ref005]\].

This study has some limitations. First, as it is generally the case in volunteer-based cohorts, participants in the NutriNet-Santé cohort were more often women, with health-conscious behaviours and higher socioeconomic position and educational levels than the general French population \[[@pmed.1003256.ref073]\], and with healthier dietary patterns \[[@pmed.1003256.ref074]\]. We might therefore have underestimated the studied associations due to a lower contrast between extreme quartiles of UPF consumption. Second, misclassifications in the NOVA categories cannot be totally excluded in spite of highly detailed food item lists and consensus reached between 8 scientists. However, this would have led to a nondifferential measurement error (in cases and non-cases), probably biasing results towards the null hypothesis. Moreover, despite adjustment for an extended range of cofactors and stratified analyses, residual confounding cannot be entirely ruled out, thus caution is needed when making causal inference. Furthermore, BMI was used to evaluate overweight and obesity: even though it is validated by the World Health Organization as a detection tool for overweight and obesity, it could be subject to misclassification depending on age, sex, and fat repartition \[[@pmed.1003256.ref075],[@pmed.1003256.ref076]\]. Recently, better estimation tools have been proposed, such as relative fat mass, enabling better prediction of adiposity but requiring clinical waist circumference measurement \[[@pmed.1003256.ref077]\], which was not available prospectively in the cohort and therefore could not be used in the present analysis. Moreover, multiple non-consecutive dietary records for the same individual are considered a valid tool to assess the usual diet \[[@pmed.1003256.ref078],[@pmed.1003256.ref079]\]. We chose to focus on baseline records in this analysis in order to comply with the prospective design and ensure that exposure (UPF consumption) preceded the outcome (BMI change or incident obesity/overweight). This design limits the risk of reverse causality, wherein participants would modify their dietary intakes due to their weight change. However, it cannot be excluded that weight changes occurring late during follow-up may be related to later dietary changes rather than to baseline diet; this probably tended to decrease the strength of the associations observed in this study. Last, the ultra-processed category covers diverse products; this exploratory approach was not designed to focus on a specific food category or to isolate a particular process/additive but has rather allowed us to explore overall exposure to UPF and to observe associations with weight gain, potentially resulting from cumulative intakes and cocktail effects of their ingredients.

Political discussions are currently ongoing in France and in Europe to decrease the number of authorized food additives. Therefore, this study contributes to the mounting level of evidence on food processing and human health needed by public policies to update dietary guidelines in the future, by integrating aspects of food processing as well as potentially more tightly regulating the policies related to food additives once high-quality results become available.

In conclusion, the results of this large-scale prospective study based on detailed and validated dietary data highlight positive associations between the dietary contribution of UPF with weight gain and risks of overweight and obesity. These associations may be partly explained by the nutritional profile of UPF, but some other dimensions specific to food processing (e.g., food matrix modification, particular food additives and contact materials, neo-formed contaminants) probably also play a key role. Further epidemiological and toxicological research is needed to better understand the underlying mechanisms. The accumulation of consistent findings on the link between UPF and health, which this study contributes to, along with the environmental non-sustainability of these products \[[@pmed.1003256.ref009]\], is leading national public health authorities---in France, e.g. \[[@pmed.1003256.ref080]\]---to recommend privileging the consumption of unprocessed/minimally processed foods and limiting the consumption of UPF. The French National Programme for Nutrition and Health (PNNS) has set a target of a 20% reduction of consumption of UPFs in France by 2022. In addition, these findings might help physicians and dietitians in clinical practice by providing evidence about the role of UPF in weight gain and obesity management.
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Lines 146-152 BMI is a poor measure of obesity. See e.g. my blog post <https://medium.com/peter-flom-the-blog/why-bmi-is-a-bad-measure-of-obesity-and-what-is-better-f8a62fc9ca49> Change in BMI at least controls for most of the peoblems. But change in BMi obscures whether the person is obese at all. A small increase in BMI for someone who is normal weight or even underweight may not be problematic. This sort of thing is hard to solve, given the failure to get good day at the start (because good data is hard) but it should be mentioned.

Line 177-178 Don\'t categorize independent variables In \*Regression Modelling Strategies\* Frank Harrell lists 11 problems with this and summarizes \"Nothing could be more disastrous\". I wrote another blog post <https://medium.com/@peterflom/what-happens-when-we-categorize-an-independent-variable-in-regression-77d4c5862b6c> showing, graphically, the things that can happen. Leave UPF continuous and use splines to investigate nonlinearitiy

Same for line 183 and 193

Table 1 - delete the p value column. P values are not relevant here, effect size is. With these N, even small differences are sig. (NOTE: It is OK to make a table liuke this with quartiles, just don\'t use quartiles in analysis. However density plots would be better here.

Peter Flom

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Reviewer \#3: Brazil, May 6th 2020

Manuscript Title: Ultra-processed food intake and weight change, overweight and obesity - Findings from the prospective NutriNet-Santé cohort

Manuscript number: PMEDICINE-D-20-00661R1

Comments to the Author

Overall, this paper is important to the community of researchers in this general area and has technical quality. The results provide a substantial advance over existing knowledge, with clear implications for public health. However, the way the paper is currently written, with much of the methodological detail and appendix missing, it is difficult to assess the methodological approach.

Abstract

\- Line 45: the number \>3500 refers to the number of items of the 24h dietary records or the number of foods in a food composition table as presented at material and methods section in line 130?

\- Line 58-61: How about weight change? include more information about weight change on the conclusion - may be useful.

Introduction

\- Overall, the introduction needs to be revised to incorporate other aspects of the complexity of overweight, obesity and weight change. The authors can then incorporate the literature on food access, for example. There are complex interactions between biological, behavioral, social and environmental factors that are involved in overweight, obesity and weight change; they need to be contemplated.

\- The author highlights the issue of obesity as an important risk factor for metabolic diseases. I suggest that the author reflects: \"Is consumption of AUP a risk factor for another risk factor? Or a risk factor for a metabolic disease (ICD-10 code E66) that is simultaneously related to other chronic non-communicable diseases? How can the study of obesity as a risk factor minimize the results found here?

\- In addition to the lack of prospective studies, explicit the study\'s contribution to the state of the art on the subject.

Material and methods

\- In the methodology, additional details regarding process of recruitment are needed. Is there any possible implications of this selection for the evidence produced by the study? I realize that additional details have already been published but it is hard to understand the process without a few more specific details.

\- In the data collection, can the authors be more specific about the number of waves that the cohort presents, the time difference between them and whether the variable outcome and explanatory were measured in all waves?

\- Line 128-129: Can the authors expand why dietary intakes from the baseline 24-hour dietary records were considered as usual dietary intakes? What are the limitations to this premise?

\- Line 131: Can the authors be more specific about the method proposed by Black? What characterizes \"under-reporters\"? What were these definitions based on? I realize that additional details have already been published but it\'s hard to understand the exclusion without a few more specific details. And how about over-reporters? They were excluded?

\- Line 146: And in the \"Obesity and overweight\" subsection how was the incidence of overweight and obesity calculated.

\- I suggest a subsection entitled \"Weight change\" (before or after obesity and overweight) or complete the subsection \"Obesity and overweight\". How was the weight change assessed? Delta? % weight loss? MBI change as present on Line 182? This is one of the outcomes of this study and its calculation must be detailed. Finally, if this outcome was assessed as a change in BMI, it is important to clarify it in the title and throughout the manuscript.

\- 159-160: Can the authors be more specific about the categories of low, moderate and high physical activity levels? It is suggested to insert the cutoff points.

\- Include indicators of the nutritional quality of the diet (alcohol, sodium, saturated fatty, dietary fiber and sugar intake, number of dietary records, fruit and vegetables, sugary drinks, Healthy and Western dietary patterns) as covariates. They were presented only in the tables and not detailed in the methods. Please, how were they obtained?

\- I suggest the exclusion of covariates present at that section, but not applied in the statistical analyses or adjustment, for example: time spent for screen watching and sedentary behaviors.

\- Line 165: Can the authors explain why exclude participants with missing anthropometric in place of apply a method of processing these missing data, for example imputation - as done for covariates (Line 178-182)? Do individuals excluded because of this information differ from those included in the study?

\- It isn\'t clear how sex-specific quartiles were accessed. That detail can lead the reader to better understand how only one data for sex-quartile were presented per quartile on table 1 for example.

\- Can the authors clarify why adjust for sex if the proportion of UPF in the diet was sex-specific quartiles?

\- Can the authors clarify why adjust for Healthy and Western dietary patterns and consumption of fruit and vegetables? Fruit and vegetables consumption do not also refers to a Healthy dietary patterns?

\- Improve the writing of the additional adjustments for sugar, fiber, sodium, and saturated fatty acid (SFA). Can the authors expand why that adjust were performed?

\- Line 202-2012: Improve the wording of the two last paragraphs of the statistical analyses. It is confusing. Perhaps, highlight that it refers to Secondary and sensitivity analyses.

\- Line 202-204: Can the authors clarify why reverse causality is a problem in this study. It is not a prospective?

Results

\- Much of the information in the tables were not included or explained in the Material and Methods section. This should be reorganized. For example, additional BMI gain, Time...

\- Figure 1: separate the exclusions of those who were \"overweight or obese\" from those \"missing from anthropometry\".

\- Table 1: The Sex-specific quartiles of the proportion of ultra-processed food intake in the total quantity of food consumed were accessed for all quartiles, correct? So include letter b for all quartiles or clarify the note for example: Cut-offs for quartiles were 10.2, 15.5 and 22.5 for men and 9.9, 15.2 and 22.1 for women, respectively.

\- Table 1 Note: Please add the full IPAQ name and Standard Deviation (SDs). And a brief explanation about IPAQ categories (low, moderate and High). The table must be self-explanatory.

\- Table 2 - Standardize the number of decimal places to the p value

\- Table 2 Note: Please include the definition of the abbreviation for BMI.

\- Table 3 - Standardize the number of decimal places to the p value

\- Table 3 Note: Please include the definition of the abbreviation for Q1, Q2, Q3 e Q4.

Discussion

\- Exclude line 319, 354 and 374

\- 296-300: I suggest rephrasing or deleting these phrases to better fit the population (adults), object of study of the manuscript.

\- The presentation of non-nutritional bioactive compounds as a hypothesis for the associations found is fantastic and real. But how these findings might inform policies and/or programming? It is urgent to include aspects of environment on that discussion.

\- The discussion would benefit from integrating the findings with additional existing literature about obesogenic environment, which would connect UPF consumption and obesity. Specially on the second paragraph in which the author highlights the nutritional quality of UPF does not appear to be entirely responsible association with weight gain.

\- Line 355: replace \"First\" for \"first\".

\- The sentences \"\[...\] However, this would have led to a non-differential measurement error (in cases and non-cases), probably biasing results towards the null hypothesis. Moreover, despite adjustment for an extended range of cofactors and stratified analyses, residual confounding cannot be entirely ruled out, thus no causality can be established \[...\]\". They are very emphatic. Causality must be established with caution, but not established.

\- The author should exclude the self-reported anthropometric as a limitation, once the data has been validated (Lassale C, Péneau S, Touvier M, Julia C, Galan P, Hercberg S, et al. Validity of web-based self551 reported weight and height: results of the Nutrinet-Santé study. J Med Internet Res. 2013 Aug 552 8;15(8):e152)

\- The author should include a paragraph with the potential of the study.

\- The conclusions would benefit from providing some insight of how these findings might inform policies and/or programming and with broader implications of the study findings.

Reference list

\- Add space between the words that make up the name of scientific journals

\#8 Obes Rev.

\#9: Int J Behav Nutr Phys Act.

\#15 and \#19: Rev Saude Publica

\#17 and \#35: Am J Clin Nutr.

\#18: Eur J Clin Nutr

\#39: Int J Obes Relat Metab

\#40 and \#42: Br J Nutr.

\#41: J Acad Nutr Diet.

\#48: Int J Public Health

\#49: Med Sci Sports Exerc.

-\#42 and \#43 are the same. Exclude one of them and review citations numbers in the manuscript.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003256.r003

Author response to Decision Letter 1

1 Jun 2020

###### 

Submitted filename: R1_SROUR_upfweight_response_final.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003256.r004

Decision Letter 2

Stone

Clare

Senior Editor

© 2020 Clare Stone

2020

Clare Stone

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

23 Jun 2020

Dear Dr. Srour,

Thank you very much for re-submitting your manuscript \"Ultra-processed food intake in association with BMI change and risk of overweight and obesity - Findings from the prospective NutriNet-Santé cohort\" (PMEDICINE-D-20-00661R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by some of the original reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Jun 30 2020 11:59PM.

Sincerely,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Can I clarify the research design, please? I suspect that the data have been collected prospectively, but that this analysis is retrospective - you use the word \"prospective\" twice in the abstract. Please can be clear about the design.

Title- please change from

Ultra-processed food intake in association with BMI change and risk of overweight and obesity - Findings from the prospective NutriNet-Santé cohort

To

Ultra-processed food intake in association with BMI change and risk of overweight and obesity; a prospective analysis of the French NutriNet-Santé cohort

Please add aggregate demographic details to go in the abstract; adjustment factors should be listed

\- p\<0.0001 -\> p\<0.001 please

THE STROBE -- can I just query the symbols used. Noting that sections and paragraphs should be used.

Comments from Reviewers:

Reviewer \#2: The authors have addressed my concerns and I now recommend publication.

Peter Flom

Reviewer \#3: Comments to the Author

Great job of responding to feedback. The manuscript still needs additional proofreading. Here are minor additional comments.

Introduction

Thanks for your explanation about obesity as a risk factor for metabolic disease. I think it\'s valuable, though the writing needs also presents obesity as a metabolic disease (ICD-10 code E66). The results can be maximized from that perspective. Presenting obesity as a disease is an important step in its management. It is important to incorporate this discourse in our work on the topic.

The first paragraph is long. I suggest that there are two paragraphs starting from line 110, which separates epidemiology from risk factors.

Line 115-121 - thanks for adding in this paragraph. I think it\'s valuable, though the writing needs a more recent or a classic citation/reference for statement about food system and built environment. We suggest: (1) Swinburn BA, Kraak VI, Allender S, Atkins VJ, Baker PI, Bogard JR, et al. The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report. The Lancet. 2019;393: 791-846. doi:10.1016/S0140-6736(18)32822-8; (2) Swinburn, B., Egger, G., Raza, F. Dissecting obesogenic environments: the development and application of a framework for identifying and prioritizing environmental interventions for obesity. Prev. Med., v.29, n.6, p.563-70, 1999.

Material and methods

Line 216-220 - insert the unit of measurement of the covariates: sugar, fibre, sodium, and saturated fatty acid (SFA), fruit, vegetables, and sugary drinks.

Line 223-228 - why italics?

Discussion

In the last paragraph, focus on France and exclude issues related to other countries like Brazil.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003256.r005

Author response to Decision Letter 2

16 Jul 2020

###### 

Submitted filename: R2_SROUR_Pointbypoint.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003256.r006

Decision Letter 3

Stone

Clare

Senior Editor

© 2020 Clare Stone

2020

Clare Stone

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

22 Jul 2020

Dear Dr. Srour,

On behalf of my colleagues and the academic editor, Dr. Aline Cristine Souza Lopes, I am delighted to inform you that your manuscript entitled \"Ultra-processed food intake in association with BMI change and risk of overweight and obesity; a prospective analysis of the French NutriNet-Santé cohort\" (PMEDICINE-D-20-00661R3) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)
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